Literature DB >> 32258564

Parkinson's Disease and development of levodopa induced motor complications: Influence of baseline features and first medical approach.

Alexandra Sofia Rua Rafael1, Joselina Maria Pinto Barbosa2, Maria José Silva Leão Rosas3, Maria Carolina Lobo Almeida Garrett1,3.   

Abstract

BACKGROUND: The introduction of levodopa in clinical practice represents a hallmark in the treatment of the neurodegenerative disease, Parkinson's Disease. However, levodopa induced motor complications, namely dyskinesias and motor fluctuations, develop in the majority of Parkinson's Disease patients.
OBJECTIVE: to identify which Parkinson's Disease's, patient's and therapeutics' initial features are more associated with dyskinesias or motor fluctuations development.
METHODS: Patients with diagnosed Parkinson's Disease attending neurology outpatient clinic at Centro Hospitalar São João were selected. For this observational study, data was retrospectively collected from patient's clinical records. A survival analysis model with univariate and multivariate regression analysis was used.
RESULTS: 87 patients with a mean of 72 ± 9.7 years were included. After a median follow-up of 6 (range 1-17) years, 35.6% patients developed dyskinesias; and with a median of 5 (range 1-16) years, 32.2% developed motor fluctuations. After multivariate analysis, the akinesia/rigidity subtype was found to have a higher risk of dyskinesias and motor fluctuations development. Age of onset ≤50 years was associated with motor fluctuations development.
CONCLUSION: In conclusion, our results suggest that Parkinson's Disease patients' initial characteristics, such as subtype or age of onset, are independently associated with the development of motor complications. Copyright 2016 PBJ-Associação Porto Biomedical/Porto Biomedical Society.

Entities:  

Keywords:  Dyskinesia; Levodopa; Motor Fluctuations; Parkinson's Disease

Year:  2016        PMID: 32258564      PMCID: PMC6806991          DOI: 10.1016/j.pbj.2016.08.001

Source DB:  PubMed          Journal:  Porto Biomed J        ISSN: 2444-8664


  41 in total

Review 1.  Treatment of Parkinson's disease: levodopa as the first choice.

Authors:  Regina Katzenschlager; Andrew J Lees
Journal:  J Neurol       Date:  2002-09       Impact factor: 4.849

2.  Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.

Authors:  Olivier Rascol; David J Brooks; Amos D Korczyn; Peter P De Deyn; Carl E Clarke; Anthony E Lang; Mona Abdalla
Journal:  Mov Disord       Date:  2006-11       Impact factor: 10.338

3.  Parkinson disease: from pathology to molecular disease mechanisms.

Authors:  David T Dexter; Peter Jenner
Journal:  Free Radic Biol Med       Date:  2013-02-04       Impact factor: 7.376

4.  Impact of the motor complications of Parkinson's disease on the quality of life.

Authors:  Stéphane Chapuis; Lemlih Ouchchane; Olivier Metz; Laurent Gerbaud; Franck Durif
Journal:  Mov Disord       Date:  2005-02       Impact factor: 10.338

5.  Impact of pramipexole on the onset of levodopa-related dyskinesias.

Authors:  Radu Constantinescu; Megan Romer; Michael P McDermott; Cornelia Kamp; Karl Kieburtz
Journal:  Mov Disord       Date:  2007-07-15       Impact factor: 10.338

6.  The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.

Authors:  Yu-Han Zhang; Bei-Sha Tang; Chen-Yuan Song; Qian Xu; Ming-Xin Lou; Zhen-Hua Liu; Ren-He Yu; Xin-Xiang Yan; Ji-Feng Guo
Journal:  Neurosci Lett       Date:  2013-10-14       Impact factor: 3.046

7.  Adherence to antiparkinson medication in a multicenter European study.

Authors:  Donald Grosset; Angelo Antonini; Margherita Canesi; Gianni Pezzoli; Andrew Lees; Karen Shaw; Esther Cubo; Pablo Martinez-Martin; Olivier Rascol; Laurence Negre-Pages; Ana Senard; Johannes Schwarz; Karl Strecker; Heinz Reichmann; Alexander Storch; Matthias Löhle; Fabrizio Stocchi; Katherine Grosset
Journal:  Mov Disord       Date:  2009-04-30       Impact factor: 10.338

Review 8.  Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments.

Authors:  Panagiotis Bargiotas; Spyridon Konitsiotis
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-22       Impact factor: 2.570

Review 9.  Treatment of Parkinson's disease in the advanced stage.

Authors:  C Ossig; H Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2013-03-10       Impact factor: 3.575

Review 10.  Survival analysis part I: basic concepts and first analyses.

Authors:  T G Clark; M J Bradburn; S B Love; D G Altman
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

View more
  2 in total

1.  Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.

Authors:  Veronica Antipova; Carsten Holzmann; Alexander Hawlitschka; Martin Witt; Andreas Wree
Journal:  Toxins (Basel)       Date:  2021-07-20       Impact factor: 4.546

Review 2.  Effects of auditory or visual stimuli on gait in Parkinsonic patients: a systematic review.

Authors:  Marta F D Trindade; Rui A Viana
Journal:  Porto Biomed J       Date:  2021-08-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.